<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Clinical Results at Nine Months of Doxycycline Hyclate Capsules 20 mg, as an Adjunct to SRP (Bioequivalent to Doxycycline Hyclate Tablets, 20 mg)    Parameter                                                                          Baseline Pocket Depth</caption>
<col></col>
<col></col>
<col></col>
<col></col>
<tbody>
<tr>
<td stylecode="     Botrule     "></td>
<td>
<content stylecode="bold">0 to 3 mm </content>
</td>
<td align="center" stylecode="     Botrule     ">
<content stylecode="bold">4 to 6 mm </content>
</td>
<td align="center" stylecode="     Botrule     ">
<content stylecode="bold">≥ 7 mm</content> </td>
</tr>
<tr>
<td> Number of Patients</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>(Doxycycline hyclate tablets 20 mg BID)</td>
<td align="center"> 90 </td>
<td align="center"> 90</td>
<td align="center"> 79</td>
</tr>
<tr>
<td> Number of Patients</td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> (Placebo)</td>
<td align="center"> 93</td>
<td align="center"> 93</td>
<td align="center"> 78</td>
</tr>
<tr>
<td stylecode="     Toprule     "> Mean Gain (SD<content stylecode="italics">
<sup>ff</sup>
</content>) in ALv<sup>†</sup>
</td>
<td stylecode="     Toprule     "> </td>
<td stylecode="     Toprule     "> </td>
<td stylecode="     Toprule     "> </td>
</tr>
<tr>
<td> Doxycycline hyclate tablets 20 mg BID</td>
<td align="center"> 0.25 (0.29)mm</td>
<td align="center"> 1.03 (0.47)mm<sup>*</sup>
</td>
<td align="center"> 1.55 (1.16)mm<sup>*</sup>
</td>
</tr>
<tr>
<td> Placebo</td>
<td> 0.20 (0.29)mm</td>
<td> 0.86 (0.48)mm</td>
<td> 1.17 (1.15)mm</td>
</tr>
<tr>
<td stylecode="     Toprule     "> Mean Decrease (SD<content stylecode="italics">
<sup> ff</sup>
</content>) in PD<sup>††</sup>
</td>
<td stylecode="     Toprule     "> </td>
<td stylecode="     Toprule     "> </td>
<td stylecode="     Toprule     "> </td>
</tr>
<tr>
<td> Doxycycline hyclate tablets 20 mg BID</td>
<td align="center"> 0.16 (0.19)mm<sup>**</sup>
</td>
<td align="center"> 0.95 (0.47)mm<sup>**</sup>
</td>
<td align="center"> 1.68 (1.07)mm<sup>**</sup>
</td>
</tr>
<tr>
<td> Placebo</td>
<td align="center"> 0.05 (0.19)mm</td>
<td align="center"> 0.69 (0.48)mm</td>
<td align="center"> 1.20 (1.06)mm</td>
</tr>
<tr>
<td stylecode="     Toprule     "> % of Sites (SD<content stylecode="italics">
<sup> ff</sup>
</content>) with loss of ALv<sup>†</sup> ≥2mm</td>
<td stylecode="     Toprule     "> </td>
<td stylecode="     Toprule     "> </td>
<td stylecode="     Toprule     "> </td>
</tr>
<tr>
<td> Doxycycline hyclate tablets 20 mg BID</td>
<td align="center"> 1.9 (4.2)%</td>
<td align="center"> 1.3 (4.5)%</td>
<td align="center"> 0.3 (9.4)%*</td>
</tr>
<tr>
<td> Placebo</td>
<td align="center"> 2.2 (4.1)%</td>
<td align="center"> 2.4 (4.4)%</td>
<td align="center"> 3.6 (9.4)%</td>
</tr>
<tr>
<td stylecode="     Toprule     "> % of Sites (SD <sup>ff</sup>) with BOP<sup>f</sup>
</td>
<td stylecode="     Toprule     "> </td>
<td stylecode="     Toprule     "> </td>
<td stylecode="     Toprule     "> </td>
</tr>
<tr>
<td> Doxycycline hyclate tablets 20 mg BID</td>
<td align="center"> 39 (19)% <sup>**</sup>
</td>
<td align="center"> 64 (18)%*</td>
<td align="center"> 75 (29)%</td>
</tr>
<tr>
<td> Placebo</td>
<td align="center"> 46 (19)%</td>
<td align="center"> 70 (18)%</td>
<td align="center"> 80 (29)%</td>
</tr>
</tbody>
</table>